Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Treace Medical Concepts, Inc. TMCI

Healthcare  —  Medical Devices
4.50 (0.04) (0.88%) as of 25 Sep
Market cap
$295.3M
P/E
0.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Treace Medical Concepts, Inc. (TMCI) Business Profile

Updated before January 2025

Company Overview

Treace Medical Concepts, Inc. (TMCI) is a medical technology company specializing in the design, development, and commercialization of innovative surgical solutions for orthopedic conditions. Founded in 2014 and headquartered in Ponte Vedra Beach, Florida, TMCI has rapidly established itself as a leader in the field of foot and ankle surgery, particularly in addressing bunion deformities. The company was founded by John T. Treace, who also serves as the Chief Executive Officer. Under his leadership, TMCI has grown significantly, leveraging its proprietary technologies and a patient-centric approach to improve surgical outcomes. The company is publicly traded on the NASDAQ under the ticker symbol TMCI.

Core Business Segments

Lapiplasty® 3D Bunion Correction™ System

TMCI’s flagship product is the Lapiplasty® 3D Bunion Correction™ System, a revolutionary surgical solution designed to correct bunion deformities in three dimensions. Unlike traditional 2D surgical approaches, the Lapiplasty® system addresses the root cause of bunions by realigning the metatarsal bone in all three planes. This system includes specialized instrumentation and implants that enable surgeons to achieve precise and reproducible results. The Lapiplasty® system has been widely adopted by orthopedic surgeons and has become a cornerstone of TMCI’s product portfolio.

Adductoplasty™ Midfoot Correction System

In addition to the Lapiplasty® system, TMCI offers the Adductoplasty™ Midfoot Correction System, which is designed to address midfoot deformities. This system complements the Lapiplasty® system and expands TMCI’s offerings in the foot and ankle surgical market.

Ancillary Products and Services

TMCI also provides a range of ancillary products and services to support its core surgical systems. These include:

  • Surgical Instruments: Specialized tools designed to enhance the precision and efficiency of surgical procedures.
  • Patient Education Resources: Comprehensive materials to educate patients about their conditions and the benefits of TMCI’s surgical solutions.
  • Training and Support for Surgeons: TMCI offers extensive training programs and ongoing support to ensure that surgeons are well-equipped to use its systems effectively.

Business Model

TMCI operates on a business model that integrates innovative products with comprehensive support services. The company generates revenue primarily through the sale of its surgical systems and related instruments. Additionally, TMCI invests heavily in surgeon education and training, which not only enhances the adoption of its products but also fosters long-term relationships with healthcare providers. By focusing on a niche market and addressing unmet needs, TMCI has created a sustainable revenue stream while positioning itself as a leader in foot and ankle surgical solutions.

Strategic Direction

TMCI is committed to expanding its product portfolio and geographic reach. The company’s strategic priorities include:

  • Product Innovation: TMCI is actively investing in research and development to introduce new surgical solutions and improve existing products.
  • Market Expansion: The company aims to increase its presence in international markets, particularly in Europe and Asia.
  • Sustainability Goals: TMCI is exploring ways to minimize its environmental footprint by adopting sustainable manufacturing practices and reducing waste.
  • Patient-Centric Approach: TMCI plans to enhance its patient education initiatives and develop new tools to improve patient outcomes.

Competitive Landscape

TMCI operates in a competitive market that includes both large medical device companies and smaller niche players. Key competitors include:

  • Stryker Corporation: A global leader in orthopedic devices, including foot and ankle solutions.
  • Zimmer Biomet: Offers a range of products for foot and ankle surgery.
  • Arthrex, Inc.: Known for its innovative surgical instruments and implants.
  • Paragon 28, Inc.: A direct competitor specializing in foot and ankle surgical solutions.

Despite the competition, TMCI differentiates itself through its proprietary technologies and focus on addressing the root causes of orthopedic conditions.

Risk Factors

TMCI faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on the success of its Lapiplasty® system, making it vulnerable to market fluctuations and competitive pressures.
  • Regulatory Challenges: As a medical device company, TMCI must navigate complex regulatory environments, which can delay product launches and increase costs.
  • Supply Chain Disruptions: Global supply chain issues could affect the availability of raw materials and components, leading to production delays.
  • Economic Conditions: Economic downturns could reduce healthcare spending and impact TMCI’s revenue.

Recent Developments

TMCI has made significant strides in recent years, including:

  • Product Launches: The introduction of the Adductoplasty™ Midfoot Correction System has expanded TMCI’s product offerings.
  • Clinical Studies: TMCI has conducted clinical studies to validate the efficacy and safety of its products, further strengthening its market position.
  • Corporate Strategies: The company has implemented initiatives to enhance operational efficiency and reduce costs.
  • Global Developments: The COVID-19 pandemic initially disrupted TMCI’s operations, but the company has since adapted by adopting digital tools for surgeon training and patient education.

Investment Considerations

Strengths

  • Innovative Products: TMCI’s proprietary technologies set it apart from competitors.
  • Strong Market Position: The company is a leader in the niche market of foot and ankle surgical solutions.
  • Growth Potential: TMCI’s focus on product innovation and market expansion positions it for long-term growth.

Risks

  • Market Dependence: Heavy reliance on a single product category.
  • Regulatory and Economic Risks: Potential challenges related to compliance and market conditions.

Conclusion

Treace Medical Concepts, Inc. is a dynamic and innovative company that has carved out a strong position in the orthopedic medical device market. With its focus on addressing unmet needs in foot and ankle surgery, TMCI is well-positioned for future growth. While the company faces certain risks, its commitment to innovation, patient-centric approach, and strategic initiatives make it an attractive option for investors and healthcare providers alike.